PHARMACEUTICAL NANOCRYSTALS: AN EXTENSIVE OVERVIEW
DOI:
https://doi.org/10.22159/ijap.2024v16i6.52257Keywords:
Pharmaceutical nanocrystals, Drug delivery, Bioavailability enhancement, Nanotoxicity, Regulatory considerations, Stabilization strategiesAbstract
In pharmaceutical development, pharmaceutical nanocrystals sized between 10 and 1000 nanometers have been found to hold promise in improving drug solubility. Since they comprise only the active pharmaceutical ingredient, nanocrystals have dramatically increased surface area-to-volume ratios, ensuring improved in vitro dissolution and solubility profiles.
In view of their strengths and limitations, different production strategies have been reviewed: methods of size reduction such as wet milling and high-pressure homogenization; the bottom-up approaches of controlled precipitation and supercritical fluid technology; and efficient ways to stabilize nanocrystal formulations aided by excipients like surfactants and polymers.
Techniques used in this characterization of nanocrystals include size analysis, surface-charge measurement, and assessment of crystalline structure. The routes of administration, such as oral, injectable, inhaled, and topical application, are reviewed alongside commercially successful products and clinical trials.
This work reviews dynamic regulatory scenarios and current challenges of large-scale production, long-term stability, and nanotoxicity evaluation. In addition, it addresses the emerging trends in nanocrystal technology in the field of personalized medicine, targeted drug delivery, and theranostic approaches associated with how nanocrystals can help optimize the outcome of a patient in drug delivery systems.
Downloads
References
Muller RH, Gohla S, Keck CM. State of the art of nanocrystals special features production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm. 2011 May;78(1):1-9. doi: 10.1016/j.ejpb.2011.01.007, PMID 21266197.
Keck CM, Muller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm. 2006 Jan;62(1):3-16. doi: 10.1016/j.ejpb.2005.05.009, PMID 16129588.
Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol. 2010 Nov;62(11):1607-21. doi: 10.1111/j.2042-7158.2010.01030.x, PMID 21039545.
Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc. 1897 Dec;19(12):930-4. doi: 10.1021/ja02086a003.
Kesisoglou F, Panmai S, WU Y. Nanosizing oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007 Jul 30;59(7):631-44. doi: 10.1016/j.addr.2007.05.003, PMID 17601629.
Junghanns JU, Muller RH. Nanocrystal technology drug delivery and clinical applications. Int J Nanomedicine. 2008;3(3):295-309. doi: 10.2147/ijn.s595, PMID 18990939, PMCID PMC2626933.
Peltonen L, Hirvonen J. Pharmaceutical nanocrystals by nanomilling: critical process parameters particle fracturing and stabilization methods. J Pharm Pharmacol. 2010 Nov;62(11):1569-79. doi: 10.1111/j.2042-7158.2010.01022.x, PMID 21039542.
Shegokar R, Muller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm. 2010 Oct 31;399(1-2):129-39. doi: 10.1016/j.ijpharm.2010.07.044, PMID 20674732.
Moschwitzer JP. Drug nanocrystals in the commercial pharmaceutical development process. Int J Pharm. 2013 Aug 30;453(1):142-56. doi: 10.1016/j.ijpharm.2012.09.034, PMID 23000841.
Gao L, Liu G, MA J, Wang X, Zhou L, LI X. Drug nanocrystals: in vivo performances. J Control Release. 2012 Jun 28;160(3):418-30. doi: 10.1016/j.jconrel.2012.03.013, PMID 22465393.
Muller RH, Keck CM. Twenty years of drug nanocrystals: where are we and where do we go? Eur J Pharm Biopharm. 2012 Jan;80(1):1-3. doi: 10.1016/j.ejpb.2011.09.012, PMID 21971369.
Wu L, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev. 2011 May 30;63(6):456-69. doi: 10.1016/j.addr.2011.02.001, PMID 21315781.
Junyaprasert VB, Morakul B. Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs. Asian J Pharm Sci. 2015 Feb 1;10(1):13-23. doi: 10.1016/j.ajps.2014.08.005.
Van Eerdenbrugh B, Van den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm. 2008 Nov 19;364(1):64-75. doi: 10.1016/j.ijpharm.2008.07.023, PMID 18721869.
Merisko Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly water-soluble compounds using wet media milling technology. Adv Drug Deliv Rev. 2011 May 30;63(6):427-40. doi: 10.1016/j.addr.2010.12.007, PMID 21223990.
Zhang HX, Wang JX, Zhang ZB, LE Y, Shen ZG, Chen JF. Micronization of atorvastatin calcium by antisolvent precipitation process. Int J Pharm. 2009 Jun 5;374(1-2):106-13. doi: 10.1016/j.ijpharm.2009.02.015, PMID 19446766.
Thorat AA, Dalvi SV. Liquid antisolvent precipitation and stabilization of nanoparticles of poorly water soluble drugs in aqueous suspensions: recent developments and future perspective. Chem Eng J. 2012 Feb 1;181-182:1-34. doi: 10.1016/j.cej.2011.12.044.
Zhang JY, Shen ZG, Zhong J, HU TT, Chen JF, MA ZQ. Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants. Int J Pharm. 2006 Oct 12;323(1-2):153-60. doi: 10.1016/j.ijpharm.2006.05.048, PMID 16828244.
Chattopadhyay P, Gupta RB. Production of griseofulvin nanoparticles using supercritical CO(2) antisolvent with enhanced mass transfer. Int J Pharm. 2001 Oct 9;228(1-2):19-31. doi: 10.1016/s0378-5173(01)00803-1, PMID 11576765.
Kakran M, Sahoo NG, LI L, Judeh Z. Fabrication of quercetin nanoparticles by anti-solvent precipitation method for enhanced dissolution. Powder Technol. 2012 Jun 1;223:59-64. doi: 10.1016/j.powtec.2011.08.021.
Bhattacharjee S. DLS and zeta potential-what they are and what they are not? J Control Release. 2016 Aug 10;235:337-51. doi: 10.1016/j.jconrel.2016.06.017, PMID 27297779.
Shekunov BY, Chattopadhyay P, Tong HH, Chow AH. Particle size analysis in pharmaceutics: principles methods and applications. Pharm Res. 2007 Feb;24(2):203-27. doi: 10.1007/s11095-006-9146-7, PMID 17191094.
Filipe V, Hawe A, Jiskoot W. Critical evaluation of nanoparticle tracking analysis (NTA) by nanosight for the measurement of nanoparticles and protein aggregates. Pharm Res. 2010 May;27(5):796-810. doi: 10.1007/s11095-010-0073-2, PMID 20204471, PMCID PMC2852530.
Clogston JD, Patri AK. Zeta potential measurement. Methods Mol Biol. 2011;697:63-70. doi: 10.1007/978-1-60327-198-1_6, PMID 21116954.
Klang V, Valenta C, Matsko NB. Electron microscopy of pharmaceutical systems. Micron. 2013 Jan;44:45-74. doi: 10.1016/j.micron.2012.07.008, PMID 22921788.
Hondow N, Brydson R, Wang P, Holton MD, Brown MR, Rees P. Quantitative characterization of nanoparticle agglomeration within biological media. J Nanopart Res. 2012 Jul;14(7):1-5. doi: 10.1007/s11051-012-0977-3.
Surwase SA, Boetker JP, Saville D, Boyd BJ, Gordon KC, Peltonen L. Indomethacin: new polymorphs of an old drug. Mol Pharm. 2013 Dec 2;10(12):4472-80. doi: 10.1021/mp400299a, PMID 24025118.
Nigmatullin R, Lovitt R, Wright C, Linder M, Nakari Setala T, Gama M. Atomic force microscopy study of cellulose surface interaction controlled by cellulose binding domains. Colloids Surf B Biointerfaces. 2004 May 15;35(2):125-35. doi: 10.1016/j.colsurfb.2004.02.013, PMID 15261045.
Wiley J. Principles and applications of thermal analysis; 2008. doi: 10.1002/9780470697702.
Sing KS. Reporting physisorption data for gas/solid systems with special reference to the determination of surface area and porosity (Recommendations 1984). Pure Appl Chem. 1985 Jan 1;57(4):603-19. doi: 10.1351/pac198557040603.
Dokoumetzidis A, Macheras P. A century of dissolution research: from noyes and whitney to the biopharmaceutics classification system. Int J Pharm. 2006 Sep 14;321(1-2):1-11. doi: 10.1016/j.ijpharm.2006.07.011, PMID 16920290.
Kazakevich YV, Lobrutto R. HPLC for pharmaceutical scientists. John Wiley & Sons; 2007 Feb 16. doi: 10.1002/0470087951.
Bajaj S, Singla D, Sakhuja N. Stability testing of pharmaceutical products. J App Pharm Sci. 2012 Mar 30:2(3):129-38. doi: 10.7324/JAPS.2012.2322.
Stuhrmann HB. Small angle scattering of X-rays. Prog Cryst Growth Char. 1989 Jan 1;18:1-19. doi: 10.1016/0146-3535(89)90023-3.
Paudel A, Raijada D, Rantanen J. Raman spectroscopy in pharmaceutical product design. Adv Drug Deliv Rev. 2015 Jul 15;89:3-20. doi: 10.1016/j.addr.2015.04.003, PMID 25868453.
Verma S, Kumar S, Gokhale R, Burgess DJ. Physical stability of nanosuspensions: investigation of the role of stabilizers on ostwald ripening. International Journal of Pharmaceutics. 2011;406(1-2):145-52. doi: 10.1016/j.ijpharm.2010.12.027.
Tuomela A, Hirvonen J, Peltonen L. Stabilizing agents for drug nanocrystals: effect on bioavailability. Pharmaceutics. 2016 May 20;8(2):16. doi: 10.3390/pharmaceutics8020016, PMID 27213435, PMCID PMC4932479.
Gigliobianco MR, Casadidio C, Censi R, Di Martino P. Nanocrystals of poorly soluble drugs: drug bioavailability and physicochemical stability. Pharmaceutics. 2018 Aug 21;10(3):134. doi: 10.3390/pharmaceutics10030134, PMID 30134537, PMCID PMC6161002.
Cerdeira AM, Mazzotti M, Gander B. Miconazole nanosuspensions: influence of formulation variables on particle size reduction and physical stability. Int J Pharm. 2010 Aug 30;396(1-2):210-8. doi: 10.1016/j.ijpharm.2010.06.020, PMID 20600732.
Rachmawati H, Al Shaal L, Muller RH, Keck CM. Development of curcumin nanocrystal: physical aspects. J Pharm Sci. 2013 Jan;102(1):204-14. doi: 10.1002/jps.23335, PMID 23047816.
Elbakry A, Wurster EC, Zaky A, Liebl R, Schindler E, Bauer Kreisel P. Layer by layer coated gold nanoparticles: size dependent delivery of DNA into cells. Small. 2012 Dec 21;8(24):3847-56. doi: 10.1002/smll.201201112, PMID 22911477.
Muller RH, Jacobs C. Buparvaquone mucoadhesive nanosuspension: preparation optimisation and long-term stability. Int J Pharm. 2002 Apr 26;237(1-2):151-61. doi: 10.1016/s0378-5173(02)00040-6, PMID 11955813.
Ghosh I, Bose S, Vippagunta R, Harmon F. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int J Pharm. 2011 May 16;409(1-2):260-8. doi: 10.1016/j.ijpharm.2011.02.051, PMID 21371540.
Pawar VK, Singh Y, Meher JG, Gupta S, Chourasia MK. Engineered nanocrystal technology: in-vivo fate targeting and applications in drug delivery. J Control Release. 2014 Jun 10;183:51-66. doi: 10.1016/j.jconrel.2014.03.030, PMID 24667572.
LU Y, LI Y, WU W. Injected nanocrystals for targeted drug delivery. Acta Pharm Sin B. 2016 Mar;6(2):106-13. doi: 10.1016/j.apsb.2015.11.005, PMID 27006893, PMCID PMC4788714.
Park K. Controlled drug delivery systems: past forward and future back. J Control Release. 2014 Sep 28;190:3-8. doi: 10.1016/j.jconrel.2014.03.054, PMID 24794901, PMCID PMC4142099.
Chiang PC, HU Y, Blom JD, Thompson DC. Evaluating the suitability of using rat models for preclinical efficacy and side effects with inhaled corticosteroid nanosuspension formulations. Nanoscale Res Lett. 2010 Apr 10;5(6):1010-9. doi: 10.1007/s11671-010-9597-y, PMID 20672144, PMCID PMC2893943.
Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. International Journal of Pharmaceutics. 2010;392(1-2):1-19. doi: 10.1016/j.ijpharm.2010.03.017.
Patel A, Patel M, Yang X, Mitra AK. Recent advances in protein and peptide drug delivery: a special emphasis on polymeric nanoparticles. Protein Pept Lett. 2014;21(11):1102-20. doi: 10.2174/0929866521666140807114240, PMID 25106908, PMCID PMC4407643.
Pireddu R, Caddeo C, Valenti D, Marongiu F, Scano A, Ennas G. Diclofenac acid nanocrystals as an effective strategy to reduce in vivo skin inflammation by improving dermal drug bioavailability. Colloids Surf B Biointerfaces. 2016 Jul 1;143:64-70. doi: 10.1016/j.colsurfb.2016.03.026, PMID 26998867.
Muller RH, Shegokar R, Keck CM. 20 y of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr Drug Discov Technol. 2011 Sep;8(3):207-27. doi: 10.2174/157016311796799062, PMID 21291409.
Patel MN, Lakkadwala S, Majrad MS, Injeti ER, Gollmer SM, Shah ZA. Characterization and evaluation of 5-fluorouracil-loaded solid lipid nanoparticles prepared via a temperature-modulated solidification technique. AAPS Pharm Sci Tech. 2014 Dec;15(6):1498-508. doi: 10.1208/s12249-014-0168-x, PMID 25035070, PMCID PMC4245423.
Sharma OP, Patel V, Mehta T. Nanocrystal for ocular drug delivery: hope or hype. Drug Deliv and Transl Res. 2016 Aug;6(4):399-413. doi: 10.1007/s13346-016-0292-0, PMID 27165145.
Tuomela A, Liu P, Puranen J, Ronkko S, Laaksonen T, Kalesnykas G. Brinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivo. Int J Pharm. 2014 Jun 5;467(1-2):34-41. doi: 10.1016/j.ijpharm.2014.03.048, PMID 24680962.
Mandal A, Bisht R, Rupenthal ID, Mitra AK. Polymeric micelles for ocular drug delivery: from structural frameworks to recent preclinical studies. J Control Release. 2017 Feb 28;248:96-116. doi: 10.1016/j.jconrel.2017.01.012, PMID 28087407, PMCID PMC5319397.
Yadollahi R, Vasilev K, Simovic S. Nanosuspension technologies for delivery of poorly soluble drugs. J Nanomater. 2015;2015(1):216375. doi: 10.1155/2015/216375.
Hollis CP, Weiss HL, Leggas M, Evers BM, Gemeinhart RA, LI T. Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery. J Control Release. 2013 Nov 28;172(1):12-21. doi: 10.1016/j.jconrel.2013.06.039, PMID 23920039, PMCID PMC3886194.
Gao W, Chen Y, Zhang Y, Zhang Q, Zhang L. Nanoparticle-based local antimicrobial drug delivery. Adv Drug Deliv Rev. 2018 Mar 1;127:46-57. doi: 10.1016/j.addr.2017.09.015, PMID 28939377, PMCID PMC5860926.
Miao X, Yang W, Feng T, Lin J, Huang P. Drug nanocrystals for cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018 May;10(3):e1499. doi: 10.1002/wnan.1499, PMID 29044971.
Cavalli R, Argenziano M, Vigna E, Giustetto P, Torres E, Aime S. Preparation and in vitro characterization of chitosan nanobubbles as theranostic agents. Colloids Surf B Biointerfaces. 2015 May 1;129:39-46. doi: 10.1016/j.colsurfb.2015.03.023, PMID 25819364.
Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA approved materials and clinical trials to date. Pharm Res. 2016 Oct;33(10):2373-87. doi: 10.1007/s11095-016-1958-5, PMID 27299311.
Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C. Nanoparticle vaccines. Vaccine. 2014 Jan 9;32(3):327-37. doi: 10.1016/j.vaccine.2013.11.069, PMID 24295808.
Cordeiro AS, Alonso MJ. Recent advances in vaccine delivery. Pharm Pat Anal. 2016;5(1):49-73. doi: 10.4155/ppa.15.38, PMID 26667309.
Simamora P, Alvarez JM, Yalkowsky SH. Solubilization of rapamycin. Int J Pharm. 2001 Feb 1;213(1-2):25-9. doi: 10.1016/s0378-5173(00)00617-7, PMID 11165091.
WU Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm. 2004 Nov 5;285(1-2):135-46. doi: 10.1016/j.ijpharm.2004.08.001, PMID 15488686.
Fakes MG, Vakkalagadda BJ, Qian F, Desikan S, Gandhi RB, Lai C. Enhancement of oral bioavailability of an HIV attachment inhibitor by nanosizing and amorphous formulation approaches. International Journal of Pharmaceutics. 2009;370(1-2):167-74. doi: 10.1016/j.ijpharm.2008.11.018.
Citrome L. Paliperidone palmitate review of the efficacy safety and cost of a new second generation depot antipsychotic medication. Int J Clin Pract. 2010 Jan;64(2):216-39. doi: 10.1111/j.1742-1241.2009.02240.x, PMID 19886879.
Sohn GK, Kwon GP, Bailey Healy I, Mirza A, Sarin K, Oro A. Topical itraconazole for the treatment of basal cell carcinoma in patients with basal cell nevus syndrome or high frequency basal cell carcinomas: a phase 2, open-label, placebo-controlled trial. JAMA Dermatol. 2019 Sep 1;155(9):1078-80. doi: 10.1001/jamadermatol.2019.1541, PMID 31339515, PMCID PMC6659355.
Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm. 2011 Nov 25;420(1):1-10. doi: 10.1016/j.ijpharm.2011.08.032, PMID 21884771.
Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev. 2013 Nov;65(13-14):1866-79. doi: 10.1016/j.addr.2013.09.019, PMID 24120656, PMCID PMC5812459.
Kumar B, Jalodia K, Kumar P, Gautam HK. Recent advances in nanoparticle-mediated drug delivery. J Drug Deliv Sci Technol. 2017 Oct 1;41:260-8. doi: 10.1016/j.jddst.2017.07.019.
Peltonen L, Hirvonen J. Drug nanocrystals versatile option for formulation of poorly soluble materials. Int J Pharm. 2018 Feb 15;537(1-2):73-83. doi: 10.1016/j.ijpharm.2017.12.005, PMID 29262301.
FDA. Considering whether an FDA-regulated product involves the application of nanotechnology. Guid Ind FDA-2010-D; 2017.
European Medicines Agency. Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product. EMA/CHMP/806058/2009/Rev. Vol. 02; 2015.
Tyner KM, Zou P, Yang X, Zhang H, Cruz CN, Lee SL. Product quality for nanomaterials: current U.S. experience and perspective. WIREs Nanomed Nanobiotechnol. 2015 Sep-Oct;7(5):640-54. doi: 10.1002/wnan.1338, PMID 25641690.
Buckley ST, Frank KJ, Fricker G, Brandl M. Biopharmaceutical classification of poorly soluble drugs with respect to enabling formulations. Eur J Pharm Sci. 2013 Sep 27;50(1):8-16. doi: 10.1016/j.ejps.2013.04.002, PMID 23583787.
Reflection paper on nanotechnology-based medicinal products for human use. European Medicines Agency; 2006.
Ehmann F, Sakai Kato K, Duncan R, Perez DE LA Ossa DH, Pita R, Vidal JM. Next-generation nanomedicines and nanosimilars: EU regulators initiatives relating to the development and evaluation of nanomedicines. Nanomedicine. 2013 May;8(5):849-56. doi: 10.2217/nnm.13.68, PMID 23656268.
International Council for Harmonisation: [ICH guidelines]; 2021. Available from: https://www.ich.org/page/ich-guidelines.
Colombo S, Cun D, Remaut K, Bunker M, Zhang J, Martin Bertelsen B. Mechanistic profiling of the siRNA delivery dynamics of lipid polymer hybrid nanoparticles. J Control Release. 2015 Mar 10;201:22-31. doi: 10.1016/j.jconrel.2014.12.026, PMID 25540904.
Siewert M, Dressman J, Brown CK, Shah VP, FIP, AAPS. FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms. AAPS Pharm Sci Tech. 2003;4(1):E7. doi: 10.1208/pt040107, PMID 12916916, PMCID PMC2750303.
Moschwitzer J, Achleitner G, Pomper H, Muller RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm. 2004 Nov;58(3):615-9. doi: 10.1016/j.ejpb.2004.03.022, PMID 15451536.
Oberdorster G. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J Intern Med. 2010 Jan;267(1):89-105. doi: 10.1111/j.1365-2796.2009.02187.x, PMID 20059646.
International Pharmaceutical Regulators Programme. Nanomedicines working group; 2021. Available from: https://www.iprp.global/working-group/nanomedicines.
International Organization for Standardization. ISO/TC 229 nanotechnologies; 2021. Available from: https://www.iso.org/committee/381983.html.
Ventola CL. Progress in nanomedicine: approved and investigational nanodrugs. PT. 2017 Dec;42(12):742-55. PMID 29234213, PMCID PMC5720487.
Keck CM, Muller RH. Nanotoxicological classification system (NCS)-a guide for the risk benefit assessment of nanoparticulate drug delivery systems. Eur J Pharm Biopharm. 2013 Aug;84(3):445-8. doi: 10.1016/j.ejpb.2013.01.001, PMID 23333302.
Muller RH, Keck CM. Twenty years of drug nanocrystals: where are we and where do we go? Eur J Pharm Biopharm. 2012 Jan;80(1):1-3. doi: 10.1016/j.ejpb.2011.09.012, PMID 21971369.
Chin WW, Parmentier J, Widzinski M, Tan EH, Gokhale R. A brief literature and patent review of nanosuspensions to a final drug product. J Pharm Sci. 2014 Oct;103(10):2980-99. doi: 10.1002/jps.24098, PMID 25099918.
Plakkot S, DE Matas M, York P, Saunders M, Sulaiman B. Comminution of ibuprofen to produce nano particles for rapid dissolution. Int J Pharm. 2011 Aug 30;415(1-2):307-14. doi: 10.1016/j.ijpharm.2011.06.002, PMID 21683776.
Kakran M, Shegokar R, Sahoo NG, Shaal LA, LI L, Muller RH. Fabrication of quercetin nanocrystals: comparison of different methods. Eur J Pharm Biopharm. 2012 Jan;80(1):113-21. doi: 10.1016/j.ejpb.2011.08.006, PMID 21896330.
Sarnes A, Kovalainen M, Hakkinen MR, Laaksonen T, Laru J, Kiesvaara J. Nanocrystal based per oral itraconazole delivery: superior in vitro dissolution enhancement versus Sporanox® is not realized in in vivo drug absorption. J Control Release. 2014 Apr 28;180:109-16. doi: 10.1016/j.jconrel.2014.02.016, PMID 24566254.
Shah DA, Murdande SB, Dave RH. A review: pharmaceutical and pharmacokinetic aspect of nanocrystalline suspensions. J Pharm Sci. 2016 Jan;105(1):10-24. doi: 10.1002/jps.24694, PMID 26580860.
Chaubal MV, Popescu C. Conversion of nanosuspensions into dry powders by spray drying: a case study. Pharm Res. 2008 Oct;25(10):2302-8. doi: 10.1007/s11095-008-9625-0, PMID 18509597.
Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect. 2005 Jul;113(7):823-39. doi: 10.1289/ehp.7339. PMID 16002369, PMCID PMC1257642.
Nel A, Xia T, Madler L, LI N. Toxic potential of materials at the nanolevel. Science. 2006 Feb 3;311(5761):622-7. doi: 10.1126/science.1114397, PMID 16456071.
Fadeel B, Fornara A, Toprak MS, Bhattacharya K. Keeping it real: the importance of material characterization in nanotoxicology. Biochem Biophys Res Commun. 2015 Dec 18;468(3):498-503. doi: 10.1016/j.bbrc.2015.06.178, PMID 26187673.
Mahmoudi M, Hofmann H, Rothen Rutishauser B, Petri Fink A. Assessing the in vitro and in vivo toxicity of superparamagnetic iron oxide nanoparticles. Chem Rev. 2012 Apr 11;112(4):2323-38. doi: 10.1021/cr2002596, PMID 22216932.
Winkler DA, Mombelli E, Pietroiusti A, Tran L, Worth A, Fadeel B. Applying quantitative structure-activity relationship approaches to nanotoxicology: current status and future potential. Toxicology. 2013 Nov 8;313(1):15-23. doi: 10.1016/j.tox.2012.11.005, PMID 23165187.
Fadeel B, Farcal L, Hardy B, Vazquez Campos S, Hristozov D, Marcomini A. Advanced tools for the safety assessment of nanomaterials. Nature Nanotech. 2018 Jul;13(7):537-43. doi: 10.1038/s41565-018-0185-0, PMID 29980781.
Sainz V, Conniot J, Matos AI, Peres C, Zupanoio E, Moura L. Regulatory aspects on nanomedicines. Biochem Biophys Res Commun. 2015 Dec 18;468(3):504-10. doi: 10.1016/j.bbrc.2015.08.023, PMID 26260323.
Patel VF, Liu F, Brown MB. Advances in oral transmucosal drug delivery. J Control Release. 2011 Jul 30;153(2):106-16. doi: 10.1016/j.jconrel.2011.01.027, PMID 21300115.
Muthu MS, Leong DT, Mei L, Feng SS. Nanotheranostics application and further development of nanomedicine strategies for advanced theranostics. Theranostics. 2014 Mar 26;4(6):660-77. doi: 10.7150/thno.8698, PMID 24723986, PMCID PMC3982135.
Norman J, Madurawe RD, Moore CM, Khan MA, Khairuzzaman A. A new chapter in pharmaceutical manufacturing: 3D-printed drug products. Adv Drug Deliv Rev. 2017 Jan 1;108:39-50. doi: 10.1016/j.addr.2016.03.001, PMID 27001902.
Patel M, Joshi G, Sawant KK. Nanotechnology in oral drug delivery: salient aspects state of art and applications. In: Functional bionanomaterials: from biomolecules to nanoparticles; 2020. p. 165-84. doi: 10.1007/978-3-030-41464-1_8.
Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nature Mater. 2013 Nov;12(11):991-1003. doi: 10.1038/nmat3776, PMID 24150417.
Prasad LK, Smyth H. 3D printing technologies for drug delivery: a review. Drug Dev Ind Pharm. 2016;42(7):1019-31. doi: 10.3109/03639045.2015.1120743, PMID 26625986.
Saritha D, Chandra Bose PS, Osmani RA, Iriventi P, Kanna S, Ravi G. Development optimization and in vitro characterization of haloperidol nanocrystals using 32 factorial design. Int J App Pharm. 2024;16(3):187-94. doi: 10.22159/ijap.2024v16i3.50412.
Abdellatif MM, Ahmed SM, EL Nabarawi MA, Teaima M. Nano delivery systems for enhancing oral bioavailability of drugs. Int J App Pharm. 2023;15(1):13-9. doi: 10.22159/ijap.2023v15i1.46758.
Published
How to Cite
Issue
Section
Copyright (c) 2024 GURUBARAN SIVANATHAN, SANJAI RAJAGOPAL, GIRIDHARA MAHADEVASWAMY, GOWTHAM ANGAMUTHU, NAGASAMY VENKATESH DHANDAPANI
This work is licensed under a Creative Commons Attribution 4.0 International License.
